AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 3794300
Drug: 6 doses
RxNorm normalized name: interferon alfa-2b,recomb. 3 million unit/0.2 mL (6 doses per pen = 18 million unit) SUBCUT PEN INJECTOR KIT (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 doses of 20 micrograms HBsAg (monthly)
Trial: 29500217
Drug: Metformin (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (up to 2 g/day)
Trial: 28112286
Drug: Training EMS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Training EMS personnel in recognizing and initiating treatment in the prehospital setting with early administration of antibiotics
Trial: 22518369
Drug: Long-acting oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting oral morphine 30 mg orally twice daily for three days
Trial: 16007008
Drug: 1% chitosan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% chitosan on 0.2% HCl in combination with methylene blue and IR laser beam (study group)
Trial: 12605026
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg cariporide
Trial: 12605026
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg cariporide
Trial: 12605026
Drug: 120 mg
RxNorm normalized name: papain 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg cariporide
Trial: 12605026
Drug: All cariporide
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All cariporide groups (20 mg, 80 mg, 120 mg)
Trial: 10382587
Drug: HOMA-CIGMA with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HOMA-CIGMA with immunoreactive insulin
Trial: 9147928
Drug: Intra-arterial cisplatinum
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-arterial cisplatinum (CDP) with 3-drug protocol (MTX, CDP, ADM)
Trial: 9147928
Drug: Intravenous cisplatinum
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous cisplatinum (CDP) with 3-drug protocol (MTX, CDP, ADM)
Trial: 9147928
Drug: Intravenous cisplatinum
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous cisplatinum (CDP) with 4-drug protocol (MTX, CDP, ADM, IFO)
Trial: 9147928
Drug: Intra-arterial cisplatinum
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-arterial cisplatinum (CDP) with 4-drug protocol (MTX, CDP, ADM, IFO)
Trial: 9147928
Drug: 4-drug protocol
RxNorm normalized name: Olay Professional Acne Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-drug protocol (MTX, CDP, ADM, IFO)
Trial: 26724101
Drug: Cannabidiol at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cannabidiol at 2-5 mg/kg per day, up-titrated to a maximum of 25 mg/kg or 50 mg/kg per day depending on study site.
Trial: 21668681
Drug: Oseltamivir (Tamiflu(®);
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oseltamivir (Tamiflu(®); Roche) 75 mg once daily prophylaxis
Trial: 21668681
Drug: Seasonal influenza
RxNorm normalized name: seasonal influenza, intradermal, preservative free
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seasonal influenza vaccine (Fluviral(®))
Trial: 18445082
Drug: Immunotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy with a vaccine containing 50% of the wild grasses Trisetum paniceum and Dactylis glomerata, administered with a schedule of 0.1 and 0.2 mL at day 1, followed by 0.3 and 0.5 mL at day 7, 0.5 mL after 2 weeks, and 0.5 mL monthly, totaling a mean of 6.5 injections over 2.3 months.
Trial: 16807413
Drug: Homocysteine-lowering treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Homocysteine-lowering treatment (daily supplement containing folate 1000 microg, B12 500 microg, and B6 10 mg)
Trial: 10740555
Drug: Regional diamorphine
RxNorm normalized name: Diamorphine
DrugBank: Diamorphine (DB01452)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regional diamorphine 2.5 mg i.v.
Trial: 9206054
Drug: Navoban (tropisetron,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Navoban (tropisetron, 5 mg)
Trial: 9206054
Drug: Kytril (granisetron,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kytril (granisetron, 3 mg)
Trial: 1317641
Drug: 5 x
RxNorm normalized name: PAD,ABDOMINAL 5 X 9 STERILE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 x 1 mg of gemeprost every 3 h
Trial: 1317641
Drug: 4 x
RxNorm normalized name: Mepilex AG 4 x 4"
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 x 1 mg of gemeprost every 6 h
Trial: 3975430
Drug: BW245C (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BW245C (150 micrograms, 6-hourly for 5 days)
Trial: 29431471
Drug: Higher protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher protein hypocaloric diet (2.0 g protein/kg/d)
Trial: 29431471
Drug: Standard-protein hypocaloric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-protein hypocaloric diet (1.0 g protein/kg/d)
Trial: 19783371
Drug: Intravenous ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ketamine infusion (0.35mg/kg/h, not to exceed 25mg/h over a 4h period) for 10 days
Trial: 19783371
Drug: Placebo infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo infusion (normal saline) for 10 days
Trial: 12641538
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid (5 mg) plus vitamin B6 (250 mg)
Trial: 9174206
Drug: Amoxicillin 875
RxNorm normalized name: amoxicillin 875 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin 875 mg orally
Trial: 9174206
Drug: Cefotaxime 1
RxNorm normalized name: cefotaxime 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotaxime 1 g intramuscularly
Trial: 4023620
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous infusion of secretin for 60 min
Trial: 4023620
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of secretin and cholecystokinin for another 60 min
Trial: 20174905
Drug: Valsartan (V)
RxNorm normalized name: Valsartan
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Valsartan (V) 160 mg once daily
Trial: 20174905
Drug: Olmesartan (O)
DrugBank: Olmesartan (DB00275)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olmesartan (O) 20 mg once daily
Trial: 20174905
Drug: Amlodipine (A)
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine (A) 10 mg once daily
Trial: 18344941
Drug: ATG (9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATG (9 mg/kg ATG Fresenius S)
Trial: 17162992
Drug: Home CPAP
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Home CPAP titration (3 nights)
Trial: 17162992
Drug: In-laboratory CPAP
RxNorm normalized name: guaifenesin
DrugBank: Guaifenesin (DB00874)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In-laboratory CPAP titration (1 night)
Trial: 11071801
Drug: Conservative strategy
RxNorm normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative strategy (persistent medical treatment)
Trial: 6381006
Drug: Continuous subcutaneous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous subcutaneous insulin infusion (CSII) using the Mill-Hill Infuser
Trial: 6381006
Drug: Multiple injections
RxNorm normalized name: sodium acetate
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multiple injections (MI) using the Medi-Jector
Trial: 29332645
Drug: Pre-meal administration
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-meal administration of Rifampicin
Trial: 29332645
Drug: Post-meal administration
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-meal administration of Rifampicin
Trial: 29332645
Drug: Pre-meal administration
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-meal administration of Pyrazinamide
Trial: 29332645
Drug: Post-meal administration
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-meal administration of Pyrazinamide
Trial: 28040121
Drug: sublingual misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: sublingual misoprostol 400 μg
Trial: 28040121
Drug: intravenous oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intravenous oxytocin 20 units
Trial: 24443547
Drug: NVP-based combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NVP-based combination antiretroviral therapy (cART)
Trial: 21414137
Drug: Maxillary 3-implant
RxNorm normalized name: ARTEMISIA CAPILLARIS LEAF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maxillary 3-implant overdentures with splinted attachment system
Trial: 21414137
Drug: Maxillary 3-implant
RxNorm normalized name: ARTEMISIA CAPILLARIS LEAF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maxillary 3-implant overdentures with unsplinted attachment system
Trial: 21414137
Drug: Conventional maxillary
RxNorm normalized name: Artemisia capillaris leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional maxillary dentures (pre-treatment)
Trial: 21414137
Drug: Maxillary 3-implant
RxNorm normalized name: ARTEMISIA CAPILLARIS LEAF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maxillary 3-implant overdentures (after 1 year)
Trial: 21414137
Drug: Maxillary 3-implant
RxNorm normalized name: ARTEMISIA CAPILLARIS LEAF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maxillary 3-implant overdentures (after 2 years)
Trial: 18158878
Drug: Triple treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple treatment plus Lactobacillus casei strain Shirota
Trial: 18158878
Drug: Triple treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple treatment alone (control)
Trial: 11791032
Drug: Quinapril (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinapril (10 mg) followed by Losartan (50 mg) or Amlodipine (5 mg)
Trial: 25170037
Drug: Osteopathic manipulative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osteopathic manipulative therapy (OMTh)
Trial: 25616647
Drug: Nimotuzumab 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimotuzumab 400 mg weekly added to standard radiochemotherapy followed by 400 mg biweekly after twelve weeks
Trial: 19299777
Drug: Melatonin 10
RxNorm normalized name: melatonin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin 10 mg tablet
Trial: 17719327
Drug: GLP-1 (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLP-1 (1.5 pmol/kg/min) as a continuous infusion beginning 12 hours before CABG and continuing for 48 hours
Trial: 17719327
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy at the discretion of the surgeon
Trial: 17719327
Drug: GLP-1 (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLP-1 (1.5 pmol/kg/min) as a continuous infusion
Trial: 14744921
Drug: diclofenac 75
RxNorm normalized name: CAPSAICIN 0.025%/DICLOFENAC 75MG KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diclofenac 75 mg twice daily for 4 weeks
Trial: 14744921
Drug: celecoxib 200
RxNorm normalized name: celecoxib 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: celecoxib 200 mg/d for 4 weeks
Trial: 14744921
Drug: diclofenac 75
RxNorm normalized name: CAPSAICIN 0.025%/DICLOFENAC 75MG KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diclofenac 75 mg twice daily at peak
Trial: 14744921
Drug: celecoxib 200
RxNorm normalized name: celecoxib 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: celecoxib 200 mg/d at peak
Trial: 14744921
Drug: diclofenac 75
RxNorm normalized name: CAPSAICIN 0.025%/DICLOFENAC 75MG KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diclofenac 75 mg twice daily for 24 hours
Trial: 14744921
Drug: celecoxib 200
RxNorm normalized name: celecoxib 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: celecoxib 200 mg/d for 24 hours
Trial: 11799264
Drug: Increased dialysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased dialysis treatment time by 2 h and reduced dry weight (group 1)
Trial: 11799264
Drug: Increased dialysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased dialysis treatment time by 2 h without changing dry weight (group 2)
Trial: 11799264
Drug: Reduced dry
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced dry weight without changing dialysis treatment time (group 3)
Trial: 7975783
Drug: Recombinant interferon
RxNorm normalized name: Recombinant Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant interferon alpha-2a (IFN alpha-2a) at a dosage of 3 x 3 million units per week for 1 year
Trial: 2596943
Drug: Minimal intervention
RxNorm normalized name: Centipeda minima whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimal intervention strategy (monthly mailed informational packets and monthly to quarterly telephone contacts)
Trial: 1122924
Drug: Fat emulsion
RxNorm normalized name: FAT EMULSION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fat emulsion infusion
Trial: 26167618
Drug: ART within
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ART within 4 weeks of starting TB treatment (Arm-1)
Trial: 26167618
Drug: ART after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ART after the intensive phase of TB treatment (Arm-2)
Trial: 26167618
Drug: ART after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ART after completing TB treatment (Arm-3)
Trial: 9562232
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil (MPA) 2 x 1 g/day during peritoneal dialysis
Trial: 9562232
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil (MPA) 2 x 1 g/day without peritoneal dialysis
Trial: 2440455
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg midodrin hydrochloride administered intravenously
Trial: 2440455
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg midodrin hydrochloride as drinking solution
Trial: 2440455
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg midodrin hydrochloride as tablet (Gutron)
Trial: 24860256
Drug: Propofol 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 1.5 mg kg(‐1), remifentanil 0.30 μg kg min(‐1), and sevoflurane 1.0 MAC
Trial: 24860256
Drug: Propofol 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 1.5 mg kg(‐1), remifentanil 0.30 μg kg min(‐1), and rocuronium 0.45 mg kg(‐1)
Trial: 22863096
Drug: Probiotic cheese
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic cheese containing Lactobacillus plantarum Tensia at a concentration of 9.6 log cfu/g for 30 consecutive days.
Trial: 22863096
Drug: Probiotic cheese
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic cheese with a daily dose of 10.3 or 8.17 log cfu/serving for 3 weeks.
Trial: 22863096
Drug: Regular semihard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular semihard Edam-type cheese with probiotic additive at a daily dose of 50g or in excess (100g) and with a probiotic daily dose of 10 log cfu for 3 weeks.
Trial: 18672532
Drug: Intermittent therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent therapy (8-week on/8-week off)
Trial: 14625133
Drug: Insulin lispro
RxNorm normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin lispro mixture (25% insulin lispro and 75% NPL) plus metformin (Mix25+M)
Trial: 14625133
Drug: Glibenclamide plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glibenclamide plus metformin (G+M)
Trial: 14625133
Drug: Insulin lispro
RxNorm normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin lispro mixture (Mix25+M)
Trial: 8370356
Drug: Calcium antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium antagonists (nisoldipine) administered before or during ischaemia
Trial: 3523396
Drug: Meperidine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meperidine (150 mg)
Trial: 3523396
Drug: Fluradoline (450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluradoline (450 mg)
Trial: 29436172
Drug: 100 mg/wk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg/wk testosterone cypionate
Trial: 29436172
Drug: 250 mg/wk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg/wk testosterone cypionate
Trial: 29436172
Drug: 500 mg/wk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg/wk testosterone cypionate
Trial: 27510295
Drug: Methylprednisolone 500
RxNorm normalized name: methylprednisolone 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone 500 mg twice a day for 3 days followed by 2 weeks of oral prednisolone 1 mg/kg/day
Trial: 27510295
Drug: 100% normobaric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100% normobaric oxygen with mask, at a flow rate of 5 liters per minute for 1 hour twice a day for two weeks
Trial: 20846257
Drug: Oral 600
RxNorm normalized name: tolmetin
DrugBank: Tolmetin (DB00500)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral 600 µg misoprostol
Trial: 20846257
Drug: Sublingual 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual 600 µg misoprostol
Trial: 18201934
Drug: KADIAN (morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KADIAN (morphine sulfate extended-release) with 240 mL 40% alcohol
Trial: 18201934
Drug: KADIAN (morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KADIAN (morphine sulfate extended-release) with water (fasted)
Trial: 18201934
Drug: KADIAN (morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KADIAN (morphine sulfate extended-release) with alcohol under fasted or fed conditions
Trial: 16620710
Drug: Preoperative hepatic
RxNorm normalized name: hepatitis nosodes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative hepatic and regional arterial infusion chemotherapy (PHRAIC)
Trial: 16620710
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (radical surgery and general venous chemotherapy)
Trial: 10967371
Drug: Fluoxetine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (20 mg daily) + Folic Acid (500 microg)
Trial: 8641579
Drug: More intensive
RxNorm normalized name: polyurethane-35 (not more than MPA.S at 40 %)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: More intensive chemotherapy during remission induction
Trial: 22992267
Drug: Eicosapentaenoic acid
RxNorm normalized name: eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eicosapentaenoic acid (EPA) 900 mg capsules thrice daily (total daily dose 2.7 g per day)
Trial: 22992267
Drug: Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules thrice daily
Trial: 18358737
Drug: Pemetrexed 500
RxNorm normalized name: pemetrexed 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed 500 mg/m² administered every 21 days
Trial: 11334901
Drug: Oral estrogens
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral estrogens
Trial: 14673604
Drug: Carrot meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carrot meal (188 g carrot purée providing 30 mg beta-carotene)
Trial: 14673604
Drug: Tomato meal
RxNorm normalized name: Tomato
DrugBank: Tomato (DB10573)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tomato meal (61 g tomato purée providing 30 mg lycopene)
Trial: 14673604
Drug: Spinach meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinach meal (260 g cooked chopped spinach providing 30 mg lutein)
Trial: 9342767
Drug: 900 mg
RxNorm normalized name: diosmin 900 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 900 mg of hypericum extract
Trial: 9342767
Drug: Bright light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bright light therapy combined with hypericum
Trial: 1469927
Drug: Ciprofloxacin (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin (250 mg twice daily for 10 days)
Trial: 1469927
Drug: Trimethoprim-sulfamethoxazole (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim-sulfamethoxazole (160 mg of trimethoprim and 800 mg of sulfamethoxazole twice daily for 10 days)
Trial: 23517838
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (control subjects)
Trial: 19034108
Drug: 10 ml
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml bupivacaine, 0.25% (TEA group)
Trial: 19034108
Drug: 10 ml
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml saline (control group)
Trial: 9124833
Drug: Dapsone 100
RxNorm normalized name: dapsone 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapsone 100 mg biweekly